Clostridium difficile and fluoroquinolones: is there a link?

Area of Science:

• Infectious Diseases
• Hospital Epidemiology
• Antimicrobial Stewardship

Background:

• Clostridium difficile infection (CDI) poses a significant threat to hospitalized patients, increasing morbidity and mortality.
• A rise in virulent CDI strains coincided with the introduction of new respiratory fluoroquinolones.
• Previous studies suggested a potential association between fluoroquinolone use and CDI occurrence.

Purpose of the Study:

• To evaluate the evidence linking fluoroquinolone use to Clostridium difficile infection.
• To determine the relative importance of antibiotic use versus infection control in CDI incidence.

Main Methods:

• Systematic review of published data on fluoroquinolone use and CDI.
• Analysis of the strength of evidence for a causal relationship.
• Comparison of the impact of fluoroquinolone use and infection-control measures.

Main Results:

• The evidence linking fluoroquinolone use to CDI is suggestive but not conclusive.
• Infection-control issues appear to be a more significant factor in CDI occurrence than fluoroquinolone use.
• Further research may be needed to clarify the precise role of fluoroquinolones.

Conclusions:

• Current evidence does not definitively establish fluoroquinolones as a primary driver of Clostridium difficile infection.
• Effective infection-control strategies are paramount in managing and preventing CDI in healthcare settings.
• The role of fluoroquinolones in CDI warrants continued, cautious evaluation alongside robust infection prevention.